长期服用抗甲状腺药物对131碘治疗Graves甲亢效果评价  

The effect of 131I in the treatment of Graves thyrotoxicosis after long-term use of anti-thyroid drug

作　　者：宋燕庆[1] 朱筠[2] 韩雪梅[1] 

机构地区：[1]新疆生产建设兵团第一师医院内分泌科,新疆维吾尔自治区阿克苏843000 [2]新疆医学院附属医院内分泌科

出　　处：《中国基层医药》2014年第19期2905-2907,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的：对长期服用抗甲状腺药物（ ATD）的131碘（ I）治疗和未长期服用ATD治疗Graves甲亢患者进行比较，探讨131 I治疗前ATD的应用价值及安全性。方法收集Graves甲亢患者62例，根据其是否经ATD长期治疗分为两组，比较其疗效、各激素水平及安全性。结果 ATD系统治疗组治疗成功率43．75％，未经ATD系统治疗组治疗成功率56．67％，两组治疗成功率差异有统计意义（Ridit＝15．152，P＝0．000）。经随访后发现，治疗后甲状腺质量、FT3、FT4、TSH水平差异无统计学意义，但两组24 h最高摄碘率差异有统计学意义（t＝6．954，P ＜0．05）；治疗期间内 ATD 系统治疗组和未经 ATD 系统治疗组出现不良反应为7例（21.88％）和3例（10．00％），两组差异有统计学意义（χ2＝4．563，P＝0．032）。结论131 I治疗前长期应用ATD治疗，可降低患者24 h最高摄碘率，降低临床疗效并增加不良反应发生率。Objective To compare the effects of Graves thyrotoxicosis patients treated by long-term use of anti-thyroid drug （ ATD） and without long-term use of ATD ,and to explore the application value and safety of ATD be-fore 131 I treatment.Methods 62 cases with Graves hyperthyroidism were divided into the two groups according to whether received the long-term ATD treatment.The curative effects,hormone level and safety were compared.Results The success rate of ATD group was 43.75%, the success rate of without ATD treatment group was 56.67%, the difference between the two groups had statistical significance （Ridit=15.152,P=0.000）.The thyroid mass,FT3, FT4 ,TSH levels after treatment between two groups had no significant differences , but the difference of the highest iodine uptake rate in 24h had significant difference （t =6.954,P＆lt;0.05）.The adverse reactions in ATD treated group and ATD untreated group were 7 cases（21.88%） and 3 cases（10.00%）,there was statistically significant difference between the two groups（χ2 =4.563,P=0.032）.Conclusion Long-term ATD therapy before 131I treatment can reduce the highest iodine uptake rate in 24h,reduce the clinical curative effect and increase adverse reaction rate .

关 键 词：抗甲状腺药 甲状腺功能亢进症 GRAVES眼病 碘放射性同位素 

分 类 号：R581.1[医药卫生—内分泌]